Session: Antiretroviral Treatment (IDWeek 2012 Meeting)

Saturday, October 20, 2012: 12:30 PM-2:00 PM

Room: SDCC Poster Hall F-H

Topical Category: H. HIV/AIDS and Other Retroviruses

Tracks: HIV-STD-TB

Presentations:

1350

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Quad) Demonstrates Comparable Efficacy and Favorable Tolerability to Efavirenz/Emtricitabine /Tenofovir DF in Patients with Adherence <95%
Edwin DeJesus, MD, FACP ; William Robbins, MD ; Fritz Bredeek, MD, PhD, FACP ; Peter Shalit, MD ; Kirsten White, PhD ; Hiu Liu, PhD ; Lauren Dau, PharmD ; Erin Quirk, MD ; David Piontkowsky, JD, MD

Posters

DeJesus 102 Adherence Subanalysis IDSA 2012 Po1350.pdf (170.0 kB)

1351	Analysis of EVG/COBI/FTC/TDF (Quad) Compared to EFV/FTC/TDF (ATR) by Race in Treatment Naive Patients W. David Hardy, MD ; Peter Ruane, MD ; Kimberly Workowski, MD, FIDSA ; Martin Rhee, MD ; David Piontkowsky, JD, MD Posters Hardy 102 Race Subanalysis IDSA 2012 Po1351.pdf (156.0 kB)

1352

Effects of Adherence and Baseline Viral Load (BL VL) on Virologic Response, with Further Safety Analyses, Among Women Compared to Men in the Phase III Week 96 ECHO and THRIVE Trials of Rilpivirine (RPV, TMC278) versus Efavirenz (EFV)
Sally Hodder, MD ; Claudia Martorell, MD, MPH, FACP ; Judith Feinberg, MD ; Princy N. Kumar, MD ; Sharon Walmsley, MD, FRCP ; Simon Vanveggel, MSc ; Laurence Rimsky, PhD ; Marita Stevens, MD

1353	Lopinavir/Ritonavir Once Daily Monotherapy Pilot Study: The MONDAKAL Study Harold Katner, MD ; Ritu Kumar, MD ; Cheryl Nylund, RN ; Shawn Jackson ; Sophia James, RN ; Emeka Obiekwe ; Kimberly Hollar, PharmD Posters Katner 10152012.pdf (2.2 MB)

1354	Beneficial effect of maraviroc, C-C chemokine receptor type 5 antagonist, as an add-on treatment for HIV-1 patients with virological response but no immunological response Masayuki Murata, MD., PhD. ; Norihiro Furusyo, MD., PhD. ; Eiichi Ogawa, MD., PhD. ; Jun Hayashi, MD., PhD.

1355

Brief Interruption of HIV Antiretroviral Therapy in Patients with Preserved CD4 Count and Virologic Suppression is Safe and Well Tolerated
Meghan Rothenberger, MD ; Ashley Haase, MD ; Alexander Khoruts, MD ; Gregory Beilman, MD ; Jeffrey Chipman, MD ; Ann Thorkelson, RN ; Cavan Reilly, PhD ; Netanya Sandler, MD ; Daniel Douek, MD, PhD ; Mario Stevenson, PhD ; Timothy Schacker, MD

CME Credits:

See more of: Poster Abstract Session

<< Previous Session | Next Session >>